Key terms
About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CORT news
Apr 15
8:11am ET
Corcept Therapeutics completes enrollment in Phase 2 DAZALS trial
Apr 11
6:00pm ET
Upcoming Deadline to Share in Corcept Therapeutics Incorporated (CORT) Class Action Settlement
Apr 08
8:11am ET
Corcept Therapeutics completes enrollment in Phase 3 ROSELLA trial
Apr 01
8:10am ET
Corcept Therapeutics completes enrollment in Phase 3 GRADIENT trial
Mar 20
5:55am ET
Corcept Therapeutics management to meet with Truist
Mar 18
8:24am ET
Corcept Therapeutics management to meet with Truist
Mar 18
7:45am ET
Truist Financial Gives a Buy Rating to Corcept Therapeutics (CORT)
Feb 17
1:00am ET
Bad News for Corcept Therapeutics Stock: This New Risk Has Been Added
Feb 16
7:45am ET
Corcept Therapeutics price target raised to $42 from $36 at Truist
Feb 16
7:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Bio-Rad Laboratories (BIO)
Feb 16
6:20am ET
Analysts’ Top Healthcare Picks: AngioDynamics (ANGO), Corcept Therapeutics (CORT)
Feb 16
6:14am ET
Corcept Therapeutics price target raised to $38 from $28 at H.C. Wainwright
Feb 15
4:52pm ET
Corcept Therapeutics announces preliminary results from CATALYST study
Feb 15
4:45pm ET
Corcept Therapeutics reports Q4 EPS 28c, consensus 26c
Feb 15
4:23pm ET
Corcept Therapeutics Reports Latest Quarterly Results and Update
Jan 24
1:29am ET
Corcept Therapeutics: Hold Rating Amidst Generic Competition and Legal Challenges
Jan 23
7:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 23
6:25am ET
Corcept Therapeutics price target lowered to $23 from $27 at Leerink
Yesterday
12:15pm ET
Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement
Apr 16
12:30pm ET
Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement
CORT Financials
Key terms
Ad Feedback
CORT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CORT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range